Bifogade filer
PR_Acarix_DeNovo granted_Eng
Kurs
+37,23%
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-12 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-06 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2025-05-15 | - | Årsstämma |
| 2025-05-12 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-15 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2024-05-14 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-21 | - | Extra Bolagsstämma 2024 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-28 | - | Extra Bolagsstämma 2023 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-12-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-23 | - | Extra Bolagsstämma 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-08-11 | - | Extra Bolagsstämma 2020 |
| 2020-05-15 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-08-16 | - | Extra Bolagsstämma 2019 |
| 2019-05-17 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-11-14 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2018-05-23 | - | Årsstämma |
| 2018-05-23 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-26 | - | Bokslutskommuniké 2017 |
| 2017-11-14 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2017-05-24 | - | Årsstämma |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Press release (MAR)
Malmö, Sweden November 25, 2020
Acarix receives US market approval for the CADScor® System
Acarix AB (publ) today announced that the US Food and Drug Administration (FDA) has approved the company’s De Novo application for marketing approval of the CADScor®System in the US.
“This is a major achievement and a significant recognition of our technology and how it can improve the diagnosis of patients with potential Coronary Artery Disease”. “In addition, it will contribute significantly to the value creation of Acarix. This approval enables us to take all measures to prepare the market launch in the USA.” said Per Persson, CEO of Acarix”.
The De Novo process is used for new products where there is no predicate device with a comparable indication in the US market to support a standard 510 (k) application. Acarix filed the De Novo application in November 2019.
For further information, please contact:
Per Persson, CEO, E-mail: per.persson@acarix.com, Phone: +46 73 600 59 90
The information disclosed above is mandatory for Acarix AB (publ) to publish pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of the above contact person on November 25, 2020 at 13:15 am (CET).
About Acarix:
Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readout is obtained in less than 10 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures. Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se)
is Certified Adviser to Acarix. For more information please visit www.acarix.com.